Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2013 financial results will be released on Thursday, November 7, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results and will address frequently asked questions from investors.

"For this quarter's call, we are evaluating a new format in order to address questions submitted via our website and other channels. The discussion will include recent inquiries regarding the prostate cancer market landscape and our clinical development program," stated Scott Cormack, President and CEO of OncoGenex. "While we remain blinded to the SYNERGY and Borealis-1 data, we will review the estimated timelines, which remain unchanged from those disclosed in our quarterly report on Form 10-Q for the second quarter of 2013."  

Questions can be submitted via email to investor-relations@oncogenex.com. Those received before noon Pacific/3:00 p.m. Eastern on Thursday, Nov. 7, will be considered for the discussion.

  • To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days. You can also monitor key inf
    '/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... STXS ) announced today the appointment of ... (EMEA) to lead the Company,s EMEA operations and sales ... utilization of its Niobe® Remote Magnetic Navigation System and ... P. Kaminski, President and CEO of Stereotaxis. ...
... Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial ... For the third quarter of 2010, the Company reported net income ... loss of $8.2 million, or $0.21 per share, for the same ... the Company reported a net loss of $10.5 million, or $0.20 ...
Cached Medicine Technology:Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 2Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 3Neurocrine Biosciences Reports Third Quarter 2010 Results 2Neurocrine Biosciences Reports Third Quarter 2010 Results 3Neurocrine Biosciences Reports Third Quarter 2010 Results 4Neurocrine Biosciences Reports Third Quarter 2010 Results 5Neurocrine Biosciences Reports Third Quarter 2010 Results 6Neurocrine Biosciences Reports Third Quarter 2010 Results 7Neurocrine Biosciences Reports Third Quarter 2010 Results 8
(Date:7/31/2014)... 2014 The 2013 edition of ... chemical listings, appellate decisions, litigation and settlement trends, ... compliance with California's Proposition 65. , The Handbook ... regulations, history and trends impacting California's Proposition 65. ... of the series which adds approximately 200 pages ...
(Date:7/31/2014)... On October 10, at the Palmer ... Applied Research Foundation, in collaboration with the University ... mesothelioma conference geared to patients and ... to mesothelioma and presented by local and regional ... include imaging, genetics, first-line therapies, surgery, chemotherapy, radiation ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Nashville, TN (PRWEB) July 31, 2014 ... TN was one of the first surgeons in the United ... the iStent, the smallest medical device ever approved ... the first surgeons to recognize the benefits of using a ... patients with glaucoma. Dr. Shofner and his colleagues now recognize ...
(Date:7/31/2014)... 2014 The vineyards are lush, and the ... And, to celebrate, folks are gearing up for the annual ... and 7, 2014 along the Leelanau Peninsula Wine Trail ... or run through the vineyards start-ing at 9:00 a.m. on ... unique course between rows of grapevines offers an experience like ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2
... , TUESDAY, Feb. 21 (HealthDay News) -- Insulin production may ... according to a new study. The findings add to ... the onset of the disease is longer than previously believed, ... thought that beta cell function completely ceased in patients with ...
... recession was the longest and most severe since World War ... at the slowest rate in over 50 years, suggesting that ... that these cut backs were not limited to Americans who ... at the University of North Carolina at Chapel Hill School ...
... , New Rochelle, NY, February 21, 2012Faith-based advocacy has ... obesity, but evidence is needed to support this assertion ... policy can contribute to promoting permanent lifestyle changes. This ... journal Childhood Obesity celebrating the second anniversary ...
... News) -- Researchers who traced the evolution of a ... livestock to humans say their findings highlight the dangers ... The international team of scientists studied methicillin-resistant Staphylococcus ... livestock-associated MRSA, which most often infects people with direct ...
... By reformulating the common cancer drug imatinib (Gleevec), researchers ... step toward improving the effectiveness of chronic pain management ... Texas MD Anderson Cancer Center. Narcotics such as ... time, tolerance to the pain-relieving effects of these drugs ...
... rescues malignant cells from destruction by extending the protective caps ... triggers resistance pathways that allow cancer to survive and spread, ... . "Telomerase is overexpressed in many advanced cancers, but ... understand what it does and how it does it," said ...
Cached Medicine News:Health News:Type 1 Diabetes May Develop More Slowly Than Thought 2Health News:Recession and high co-pays tied to fewer colonoscopy screenings among people with health insurance 2Health News:Childhood obesity -- can faith-based organizations make a difference? 2Health News:Pig-to-Human 'Superbug' May Be Due to Animal Antibiotics 2Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 3Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 4
Inquire...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: